A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy

Cancer

Volumn 107, Issue 4, 2006, Pages 799-805

  Kim, Heung T ^a   Han, Ji Youn ^a   Lee, Dae H ^a   Chun, Jong H ^a   Lee, Hong G ^a   Lee, Jae J ^a   Kim, Hyae Y ^a   Lee, Sung Y ^a   Lee, Jin S ^a  

^a National Cancer Center   (South Korea)

Author keywords

Cisplatin; Irinotecan; Non small cell lung cancer; Second line

Indexed keywords

CAPECITABINE; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; GRANISETRON; IRINOTECAN; LOPERAMIDE; NAVELBINE; ONDANSETRON; PEMETREXED;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33747189764     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22063     Document Type: Article

References (18)

1. Pfister DG, Johnson DH, Azzoli CG, et al. American society of clinical oncology treatment of unresectable non-small cell lung cancer guideline: Update 2003. J Clin Oncol. 2004;22:330-353.
2. Shepherd F, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-2103.
3. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
4. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
5. Takeda K, Negoro S, Tamura T, et al. Docetaxel (D) versus docetaxel plus gemcitabine (DG) for second-line treatment of non-small cell lung cancer (NSCLC): Results of a JCOG randomized trial (JCOG0104). Proc Am Soc Clin Oncol. 2004;23:622.
6. Pectasides D, Farmakis D, Pectasides M, et al. Docetaxel versus docetaxel plus irinotecan as second line chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized phase II trial. Proc Am Soc Clin Oncol. 2004;23:621.
7. Jagasia MH, Langer CJ, Johnson DH, et al. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: A multicenter phase II study. Clin Cancer Res. 2001;7:68-73.
8. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1998;10:1-110.
9. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281-1288.
10. Rothenberg ML. CPT-11: An original spectrum of clinical activity. Semin Oncol. 1996;23(Suppl 3):S21-S26.
11. Masuda N, Fukuoka M, Fujita A, et al., for CPT-11 Lung Cancer Study Group. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. Br J Cancer. 1998;78:251-256.
12. DeVore RF, Johnson DH, Crawford J, et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 1999;17:2710-2720.
13. Cardenal F, Domine M, Massuti B, et al. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: A multicentre phase II study. Lung Cancer. 2003;39:201-207.
14. Han J-Y, Lim H-S, Lee DH, et al. Randomized phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2006;106:873-880.
15. CPT-11 Cooperative Study Group. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother. 1991;18:1013-1019.
16. Nakai H, Fukoka M, Furuse K, et al. An early phase II study of CPT-11 in primary lung cancer. Gam To Kagaku Ryoho. 1991;18:607-612.
17. Saltz LB, Spriggs D, Schaaf LJ, et al. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J Clin Oncol. 1998;16:3858-3865.
18. Georgoulias V, Agelidou A, Syrigos K, et al. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: A multicenter randomised phase II study. Br J Cancer. 2005;93:763-769.